Michael Doyle
About Michael Doyle
Michael Doyle is the Director of Discovery Biotherapeutics Protein Science at Bristol-Myers Squibb in Princeton, New Jersey, with extensive experience in protein biophysical chemistry and therapeutic drug discovery.
Current Role at Bristol-Myers Squibb
Michael Doyle serves as the Director of Discovery Biotherapeutics Protein Science at Bristol-Myers Squibb, based in Princeton, New Jersey. His role involves leading a team in the discovery and development of new biotherapeutic drugs. He applies his extensive expertise in biophysics and protein science to enhance the development of protein therapeutic candidates.
Previous Experience at Bristol-Myers Squibb
From 2000 to 2019, Michael Doyle held the role of Sr. Principal Scientist in Protein Therapeutics Discovery at Bristol-Myers Squibb. During his 19-year tenure, he was instrumental in the protein engineering and drug discovery processes. He utilized various biophysical techniques to accelerate the optimization of therapeutic proteins, contributing to multiple discovery projects.
Earlier Career at GSK
Before joining Bristol-Myers Squibb, Michael Doyle worked at GSK as Assistant Director of Structural Biology from 1993 to 2000. His work focused on structural biology, where he developed innovative approaches to understanding protein structures and their implications in drug discovery. His efforts added significant value to GSK's research and development initiatives.
Educational Background
Michael Doyle's educational journey includes earning a Ph.D. in Biophysical Chemistry from the University of Colorado at Boulder, where he studied from 1982 to 1987. He pursued Post-Doctoral studies at The Johns Hopkins University in Biophysical Chemistry from 1988 to 1989, and at Washington University in St. Louis School of Medicine in Molecular Biophysics from 1990 to 1992.
Expertise in Biophysical Chemistry
Michael Doyle has published over 80 papers on protein biophysical chemistry. His expertise covers biomolecular binding mechanisms, employing technologies like SPR, ITC, AUC, Thermal Stability Perturbation, and Bio-Layer Interferometry. He strategically uses multiple bioanalytical technologies to assess the developability of protein therapeutic candidates.